Novita Pharmaceuticals and China Resources Double Crane Pharmaceutical Enter into an Exclusive License Agreement to Develop and Commercialize Fascin Inhibitor in China
Novita Pharmaceuticals to Present its Fascin Inhibitor NP-G2-044 Phase 1A Results in Patients with Advanced and Metastatic Solid Tumors at 2021 ASCO Annual Meeting